STUDY IN NATURE MEDICINE SHOWS SUPERIOR OUTCOMES FOR PATIENTS IN LLS’S PARADIGM-SHIFTING BEAT AML CLINICAL TRIAL

26 October, 2020

Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.

The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.

 
Related News
Dana Callow to Speak at Cancer Moonshot Summit
06.29.16
Boston Millennia Partners’ Dana Callow to Speak at Cancer Moonshot Summit. Simultaneous events will take place at the same time throughout the country to improve awareness of the program and gain support for funding research. Representatives from major pharmaceutical companies and service providers including Takeda, Syapse, and Foundation Medicine well as researchers from the area will speak about the Moonshot and their roles in finding a cure. The White House is sponsoring The National Cancer Moonshot summit. Vice President Joe Biden will speak on behalf of the program and subsequently there will be panel discussions by leading cancer specialists and patient advocates. As a Board Member of the National Leukemia Society Dana will address how non-profit organizations can positively impact the effort to find cures and improve patient care. Location: MGH Cancer Center, Lawrence House, 1st Floor Conference Room, 10 North Grove St., Boston MA Please contact liz@bmpvc.com for the speaker guide Read Full Release